entertainment -WSS

entertainment

author：focus 2025-10-02 23:59:51 - browse：4

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Boston's new lab space is opening empty

hotspot

WSS

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Medicare coverage of Wegovy, once blocked, now looks possible

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Trump Jan. 6 attorney John Lauro is ex

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

focus

entertainment

focus

Hollywood unions extend contract negotiations for actors

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

WuXi out of biotech trade group, U.S. and China relations to blame

Trump demands the U.S. pay no more for drugs than other countries … again

Pushing for an NIH office for post

Bright Health sells Medicare Advantage business to Molina

President Biden's budget: Here's what you might have missed

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

knowledge

FDA advisers back CAR

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

NYC plans to house migrants on an island in the East River

'The Exorcist' director William Friedkin dead at 87

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Wikipedia

hotspot

hotspot

Wikipedia